ZAPI Stakeholders Final Conference
February 4-5, 2021
A Virtual Meeting
INFORMATION ABOUT THE MEETING HERE
In March 2015, IMI (Innovative Medicine Initiative - https://www.imi.europa.eu) launched ZAPI (Zoonotic Anticipation and Preparedness Initiative) to set up methodologies and platform technologies that would be ready to put into production for vaccines and neutralizing monoclonal antibodies to efficiently counter emerging or remerging zoonotic viruses.
“The objective is to demonstrate that we can deliver on these platforms, using three different prototype models of diseases that occurred in the recent past and which are zoonotic in nature.” The viruses that [have been] used as models are Middle East respiratory syndrome coronavirus (MERS-CoV); Schmallenberg virus; and Rift Valley Fever virus’. IMI ZAPI Interview
Six years later, the ZAPI project has made great strides in vaccine and antibody design, and new approaches for achieving the “surge manufacturing capacity” objective.
The Final Stakeholders Global Meeting will present an overview of the main findings and key learnings from the ZAPI project partnership’s experience for improving our One Health preparedness status for facing effectively future pandemics.
The ZAPI project benefits from the assistance and financial support of
IMI and the European Commission, and in-kind contributions from EFPIA partners.
Many infectious diseases, including influenza and Ebola, can be transmitted to humans from animals (and vice-versa). Known as zoonoses, these diseases represent a serious threat to both human and animal health. ZAPI brings together experts in human and animal health to create new platforms and technologies that will facilitate a fast, coordinated, and practical response to new infectious diseases as soon as they emerge.
25 outbreaks in 20 years
New infectious diseases are emerging at an increasing frequency in the EU and other regions of the world, with the potential to profoundly impact public and animal health, and strongly disrupt local and international economies. The majority of these diseases are zoonoses, meaning they originate in or are transmitted by animals. In the last 20 years, there have been 25 documented emerging diseases that moved from wild or domestic animals to human populations. It is highly probable that zoonoses that spread rapidly (many of them are insect-borne diseases) in one or several EU countries will continue or increase due to environmental and demographic changes. The EU has already been affected by many zoonoses over the past 20 years, for example, West Nile virus, chikungunya and influenza H5N1.